专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

WO2017214068A1 SYSTEMS AND METHODS FOR PATIENT STRATIFICATION AND IDENTIFICATION OF POTENTIAL BIOMARKERS 审中-公开
标题翻译：用于病人分层和潜在生物标志识别的系统和方法
公开(公告)号：WO2017214068A1
公开(公告)日：2017-12-14
申请号：PCT/US2017/036020
申请日：2017-06-05
申请人： BERG LLC
发明人： NARAIN, Niven, Rajin , AKMAEV, Viatcheslav, R. , RODRIGUES, Leonardo , MILLER, Gregory, Mark
IPC分类号： G01N33/48 , G06F19/20 , A61B5/00
摘要： Disclosed herein are methods and systems for identifying one or more potential biomarkers for a clinical outcome related to administration of an agent. The method includes processing molecular profile data for a plurality of subjects where the molecular profile data includes data obtained before, during and/or after administration of an agent to the plurality of subjects. The method also includes processing clinical records data for the subjects, where the clinical records data includes clinical outcome data, integrating the processed molecular profile data and the processed clinical records data for the subjects and storing in a database as merged data, selecting two or more subsets of the merged data using one or more criteria based on the clinical records data to generate two or more selected data sets, and analyzing one or more of the selected data sets to identify one or more potential biomarkers for a clinical outcome related to administration of the agent.
摘要翻译：本文公开了用于鉴定与施用药剂有关的临床结果的一种或多种潜在生物标志物的方法和系统。该方法包括处理多个对象的分子谱数据，其中分子谱数据包括在向多个对象施用药剂之前，期间和/或之后获得的数据。该方法还包括处理对象的临床记录数据，其中临床记录数据包括临床结果数据，整合处理后的分子概况数据和处理的对象的临床记录数据，并作为合并数据存储在数据库中，选择两个或更多个使用基于临床记录数据的一个或多个标准生成两个或更多个选择的数据集合，并且分析一个或多个选择的数据集合以识别一个或多个潜在生物标志物用于与施用代理。

62. 发明申请

WO2017214064A1 PREVENTING OR MITIGATING CHEMOTHERAPY INDUCED ALOPECIA USING VITAMIN D 审中-公开
标题翻译：用维生素D预防或减轻化疗引起的异常
公开(公告)号：WO2017214064A1
公开(公告)日：2017-12-14
申请号：PCT/US2017/036011
申请日：2017-06-05
申请人： BERG LLC , NARAIN, Niven, Rajin
发明人： NARAIN, Niven, Rajin , SARANGARAJAN, Rangaprasad , JIMENEZ, Joaquin, J.
IPC分类号： A61K8/67 , A61K31/593
摘要： The invention provides methods and pharmaceutical compositions for preventing or mitigating chemotherapy-induced alopecia (CIA). The pharmaceutical compositions of the invention comprise an effective amount of a vitamin D compound in a topical formulation. The invention has broad applications in chemotherapies that induce alopecia, for example taxane based chemotherapy for cervical cancer, endometrial cancer, ovarian cancer, fallopian tube cancer, primary peritoneal carcinoma, soft tissue sarcoma, or bone sarcoma. The pharmaceutical compositions of the invention can be advantageously administered before and/or concurrent with the chemotherapy.
摘要翻译：本发明提供了用于预防或减轻化疗引起的脱发（CIA）的方法和药物组合物。本发明的药物组合物在局部制剂中包含有效量的维生素D化合物。本发明在诱导脱发的化疗中有广泛的应用，例如用于宫颈癌的紫杉烷类化疗，子宫内膜癌，卵巢癌，输卵管癌，原发性腹膜癌，软组织肉瘤或骨肉瘤。本发明的药物组合物可以有利地在化疗之前和/或同时给药。

63. 发明申请

WO2016094425A1 USE OF MARKERS INCLUDING FILAMIN A IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER 审中-公开
标题翻译：使用包括FILAMIN A在内的标记物进行诊断和治疗前列腺癌
公开(公告)号：WO2016094425A1
公开(公告)日：2016-06-16
申请号：PCT/US2015/064530
申请日：2015-12-08
申请人： BERG LLC
发明人： NARAIN, Niven, Rajin , VISHNUDAS, Vivek, K. , SARANGARAJAN, Rangaprasad , AKMAEV, Viatcheslav, R.
IPC分类号： C07K16/18 , G01N33/574
CPC分类号： G01N33/57434 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N2333/47 , G01N2333/4742
摘要： Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including the detection of levels of variety of biomarkers diagnostic of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, and LY9. Additionally, age can be used as a predictor variable. The invention also provides methods of treating prostate cancer which rely on diagnostic information obtained based on the detection of biomarkers of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, LY9, and/or age. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.
摘要翻译：提供了用于诊断受试者中前列腺癌存在的方法，所述方法包括检测前列腺癌诊断的生物标志物的多样性水平，包括单独的丝氨酸A或与一种或多种另外的前列腺癌生物标志物组合， PSA，角蛋白4，角蛋白7，角蛋白8，角蛋白15，角蛋白18，角蛋白19，微管蛋白β3，丝氨蛋白B和LY9。此外，年龄可以用作预测变量。本发明还提供了依赖于基于前列腺癌生物标志物的检测而获得的诊断信息的方法，所述诊断信息包括单独的丝氨酸A或与一种或多种另外的前列腺癌生物标志物组合，包括PSA，角蛋白4，角蛋白7，角蛋白8，角蛋白15，角蛋白18，角蛋白19，微管蛋白β3，丝氨蛋白B，LY9和/或年龄。还提供了用于检测本发明的生物标志物的试剂盒和试剂盒形式的组合物。

64. 发明申请

WO2015035094A1 METHODS OF TREATMENT OF CANCER BY CONTINUOUS INFUSION OF COENZYME Q10 审中-公开
标题翻译：连续输注酵素治疗癌症的方法Q10
公开(公告)号：WO2015035094A1
公开(公告)日：2015-03-12
申请号：PCT/US2014/054155
申请日：2014-09-04
申请人： BERG LLC
发明人： NARAIN, Niven, Rajin , SARANGARAJAN, Rangaprasad , GRAY, Thomas, Mitchell , MCCOOK, John, Patrick , JIMENEZ, Joaquin, J.
IPC分类号： A61K38/43
CPC分类号： A61K9/0019 , A61K31/122 , A61K31/337 , A61K31/513 , A61K31/519 , A61K31/704 , A61K31/7068 , A61K31/7076 , A61K38/43 , A61K2300/00
摘要： The invention provides regimens and methods for the treatment of cancer comprising continuous infusion of coenzyme QIO. The coenzyme QIO may be administered as a monotherapy, or in combination with an additional agent, such as an anticancer agent, a chemotherapeutic agent, or an anti- angiogenic agent. The coenzyme QIO may be administered at two or more different rates.
摘要翻译：本发明提供了用于治疗癌症的方案和方法，其包括连续输注辅酶Q10。辅酶Q10可以作为单一疗法施用，或与另外的药剂例如抗癌剂，化学治疗剂或抗血管生成剂组合施用。辅酶QIO可以以两种或更多种不同的速率给药。

65. 发明申请

WO2014168993A1 TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES 审中-公开
标题翻译：使用COENZYME Q10联合治疗癌症治疗
公开(公告)号：WO2014168993A1
公开(公告)日：2014-10-16
申请号：PCT/US2014/033402
申请日：2014-04-08
申请人： BERG LLC
发明人： NARAIN, Niven, Rajin , SARANGARAJAN, Rangaprasad
IPC分类号： A61K31/122 , A61P35/02 , G01N33/53
CPC分类号： A61K31/122 , A61K31/4745 , A61K31/513 , A61K31/704 , A61K31/7068 , A61K33/24 , A61K39/39558 , A61K45/06 , C07K16/32 , A61K2300/00
摘要： Presented herein are methods for the treatment of oncological disorders by the co¬ administration of CoQ10 formulations and chemo therapeutic agents and/or surgery. The CoQ10 formulations may be at least one of intravenous, topical, or by inhalation. The chemo therapeutic agents may be at least one of antimetabolites or anthracyc lines. Co-administration of the CoQ10 formulations may be prior to, concurrent or substantially concurrent with, intermittent with or subsequent to the administration of the chemotherapy.
摘要翻译：本文提出的是通过共同施用CoQ10制剂和化学治疗剂和/或手术来治疗肿瘤疾病的方法。 CoQ10制剂可以是静脉内，局部或吸入中的至少一种。化学治疗剂可以是抗代谢物或蒽环中的至少一种。 CoQ10制剂的共同给药可以在与化疗的给药或随后进行间歇的同时或基本上同时进行。

66. 发明申请

WO2013176694A8 INTERROGATORY CELL-BASED ASSAYS FOR IDENTIFYING DRUG-INDUCED TOXICITY MARKERS 审中-公开
公开(公告)号：WO2013176694A8
公开(公告)日：2013-11-28
申请号：PCT/US2012/054323
申请日：2012-09-07
申请人： BERG LLC , NARAIN, Niven, Rajin , SARANGARAJAN, Rangaprasad , VISHNUDAS, Vivek, K.
发明人： NARAIN, Niven, Rajin , SARANGARAJAN, Rangaprasad , VISHNUDAS, Vivek, K.
IPC分类号： G01N33/48 , G01N33/53 , G06F19/12
摘要： Described herein is a discovery Platform Technology for analyzing a drug- induced toxicity condition, such as cardiotoxicity via model building.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式